Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanxi Yongjin Group is a Chinese pharmaceutical and industrial conglomerate primarily known for its dominance in the production of antipsychotic and neurological medications. Through its subsidiary, Shanxi Yongjin Pharmaceutical, the company operates as a major production base for several key psychiatric APIs and finished dosages, including chlorpromazine and perphenazine. The company maintains GMP-certified facilities and serves both the Chinese domestic market and international export markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanxi Yongjin Group.